M J Landray
Overview
Explore the profile of M J Landray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reith C, Staplin N, Herrington W, Stevens W, Emberson J, Haynes R, et al.
BMC Nephrol
. 2017 May;
18(1):147.
PMID: 28460629
Background: Reducing LDL cholesterol (LDL-C) with statin-based therapy reduces the risk of major atherosclerotic events among patients with chronic kidney disease (CKD), with no evidence of an excess risk of...
2.
Bowman L, Chen F, Sammons E, Hopewell J, Wallendszus K, Stevens W, et al.
Am Heart J
. 2017 Apr;
187:182-190.
PMID: 28454801
Methods: The REVEAL study is a randomized, double-blind, placebo-controlled clinical trial that is assessing the efficacy and safety of adding anacetrapib to effective LDL-lowering treatment with atorvastatin for an average...
3.
Emberson J, Haynes R, Dasgupta T, Mafham M, Landray M, Baigent C, et al.
J Intern Med
. 2010 Mar;
268(2):145-54.
PMID: 20337853
Objective: To assess the relevance of cystatin C, as a marker of mild-to-moderate renal impairment, for vascular and nonvascular mortality in older people. Design: Prospective cohort study. Setting: Re-survey in...
4.
Landray M, Baigent C
Evid Based Cardiovasc Med
. 2005 Dec;
5(2):32-3.
PMID: 16379875
No abstract available.
5.
Landray M, Toescu V, Kendall M
J Clin Pharm Ther
. 2002 Aug;
27(4):233-42.
PMID: 12174024
This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers,...
6.
Lip G, Edmunds E, Nuttall S, Landray M, Blann A, Beevers D
J Hum Hypertens
. 2002 Jun;
16(5):333-6.
PMID: 12082494
Malignant hypertension (MHT) is a rare and severe form of hypertension characterised by arteriolar necrosis and severe vascular damage, leading to stroke, myocardial infarction and death. We hypothesised that in...
7.
Landray M, Edmunds E, Li-Saw-Hee F, Hughes B, Beevers D, Kendall M, et al.
QJM
. 2002 Feb;
95(3):165-71.
PMID: 11865172
Background: Low-density lipoprotein (LDL) consists of a heterogeneous group of particles of varying size and electrophoretic mobility. A predominance of small, more mobile particles is a risk factor for cardiovascular...
8.
Landray M, Thambyrajah J, McGlynn F, Jones H, Baigent C, Kendall M, et al.
Am J Kidney Dis
. 2001 Sep;
38(3):537-46.
PMID: 11532686
Patients with chronic renal impairment (CRI) are at greatly increased risk for premature vascular disease; however, little is known about its evolution. This paper describes a cohort of patients with...
9.
Thambyrajah J, Landray M, Jones H, McGlynn F, Wheeler D, Townend J
J Am Coll Cardiol
. 2001 Jun;
37(7):1858-63.
PMID: 11401123
Objectives: This study was designed to determine the effects of folic acid therapy on endothelial function in patients with coronary artery disease (CAD). Background: Hyperhomocysteinemia, a risk factor for CAD,...
10.
Edmunds E, Landray M, Li-Saw-Hee F, Hughes B, Beevers D, Lip G
QJM
. 2001 Jun;
94(6):327-32.
PMID: 11391031
Low-density lipoprotein (LDL) consists of a heterogeneous group of particles of differing size, density and electrophoretic mobility, smaller particles being more atherogenic. A high proportion of small LDL particles is...